Abstract |
Treatment for fragile X syndrome and related autism spectrum disorders has long been thought to be effective only during a narrow window early in development. In this issue of Neuron, Michalon et al. (2012) dispel this myth.
|
Authors | Aditi Bhattacharya, Eric Klann |
Journal | Neuron
(Neuron)
Vol. 74
Issue 1
Pg. 1-3
(Apr 12 2012)
ISSN: 1097-4199 [Electronic] United States |
PMID | 22500622
(Publication Type: Journal Article, Comment)
|
Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
Chemical References |
- 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine
- Excitatory Amino Acid Antagonists
- Imidazoles
- Pyridines
- Receptor, Metabotropic Glutamate 5
- Receptors, Metabotropic Glutamate
|
Topics |
- Animals
- Excitatory Amino Acid Antagonists
(therapeutic use)
- Fragile X Syndrome
(drug therapy)
- Imidazoles
(therapeutic use)
- Male
- Pyridines
(therapeutic use)
- Receptor, Metabotropic Glutamate 5
- Receptors, Metabotropic Glutamate
(drug effects)
|